Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma. Results from the European Society for Thoracic Surgeons Lung Neuroendocrine Tumours Retrospective Database
BJECTIVES: Large-cell neuroendocrine carcinoma (LCNC) is a rare tumour characterized by aggressive biological behaviour and poor prognosis. Due to its rarity and the lack of randomized clinical trials, the best treatment is still under debate. Some recent reports indicate that adjuvant chemotherapy (CT) may have a beneficial effect on survival.